Who is eligible for clinical trial NCT05981703?

Participants must meet protocol criteria for Advanced Solid Tumor. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05981703 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-01

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (NCT05981703)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: BeOne Medicines

🩺 Plain-English Summary (8th-Grade Level)

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (11 items).

Location: City of Hope National Medical Center — Duarte, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
Phase 1a: Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors that are immune-sensitive who have previously received standard systemic therapy, or for whom treatment is not available or not tolerated, or for whom treatment is determined not appropriate based on investigator's judgment and who have not received prior therapy targeting hematopoietic progenitor kinase 1 (HPK1).
Phase 1b: Participants with histologically confirmed locally advanced unresectable or metastatic tumor types and who have not had prior systemic treatment. Participants who received prior systemic therapy in a neo-adjuvant or adjuvant setting with curative intent for nonmetastatic disease must have experienced a disease-free interval of ≥ 6 months from the last dose of systemic therapy prior to the first dose of study treatments.
≥ 1 measurable lesion per RECIST v1.1.
Able to provide an archived tumor tissue sample.
Adequate organ function.
Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for ≥ 90 days after the last dose of BGB-26808, or for ≥ 120 days after the last dose of tislelizumab, or for ≥ 180 days after the last dose of chemotherapy.
Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 90 days after the last dose of BGB-26808, or for ≥ 120 days after the last dose of tislelizumab, or for ≥ 180 days after the last dose of chemotherapy.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, anti-CTLA4, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention.
Clinically significant bleeding from the gastrointestinal tract within 28 days before the first dose of study treatment(s).
Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
Active autoimmune diseases or history of autoimmune diseases that may relapse
Any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study treatment(s).
History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases.
Uncontrolled diabetes.
Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study treatment(s). Note: Other protocol defined Inclusion/Exclusion criteria may apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (28 Sites)

City of Hope National Medical Center — Duarte, California
University of Southern California Norris Comprehensive — Los Angeles, California
Yale University Yale Cancer Center — New Haven, Connecticut
Sylvester Cancer Center, University of Miami — Miami, Florida
University of Michigan Health System — Ann Arbor, Michigan
John Theurer Cancer Center Hackensack University Medical Center — Hackensack, New Jersey
Icahn School of Medicine At Mount Sinai — New York, New York
Providence Portland Medical Center — Portland, Oregon
The University of Texas Md Anderson Cancer Center — Houston, Texas
Southside Cancer Care — Miranda, New South Wales
Macquarie University — North Ryde, New South Wales
Icon Cancer Centre Kurralta Park — Kurralta Park, South Australia
Linear Clinical Research — Nedlands, Western Australia
The First Affiliated Hospital of Anhui Medical Universitygaoxin Branch — Hefei, Anhui
Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
Hubei Cancer Hospital — Wuhan, Hubei
Tongji Hospital,Tongji Medical College of Hustsino French New City Branch — Wuhan, Hubei
The First Hospital of China Medical University Hunnan Branch — Shenyang, Liaoning
Jining No1 Peoples Hospital West Branch — Jining, Shandong
Yantai Yuhuangding Hospital — Yantai, Shandong
Shanghai East Hospital Branch Hospital — Shanghai, Shanghai Municipality
Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital — Chengdu, Sichuan
Hangzhou First Peoples Hospital — Hangzhou, Zhejiang
Taizhou Hospital of Zhejiang Province (East) — Taizhou, Zhejiang

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗